J.Safra Asset Management Corp Makes New Investment in Vaxcyte, Inc. $PCVX

J.Safra Asset Management Corp bought a new stake in Vaxcyte, Inc. (NASDAQ:PCVX) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 12,564 shares of the company’s stock, valued at approximately $730,000.

Other hedge funds have also recently modified their holdings of the company. Janus Henderson Group PLC grew its holdings in shares of Vaxcyte by 23.8% during the first quarter. Janus Henderson Group PLC now owns 16,575,875 shares of the company’s stock worth $960,231,000 after purchasing an additional 3,188,687 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its position in shares of Vaxcyte by 35.9% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 11,296,333 shares of the company’s stock valued at $521,213,000 after purchasing an additional 2,981,038 shares during the period. Wellington Management Group LLP grew its stake in Vaxcyte by 18.5% during the 4th quarter. Wellington Management Group LLP now owns 5,966,310 shares of the company’s stock worth $275,286,000 after buying an additional 933,539 shares during the last quarter. State Street Corp increased its position in Vaxcyte by 4.1% during the fourth quarter. State Street Corp now owns 4,980,005 shares of the company’s stock worth $229,777,000 after buying an additional 194,116 shares during the period. Finally, Paradigm Biocapital Advisors LP lifted its stake in Vaxcyte by 7.5% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 4,068,020 shares of the company’s stock valued at $187,698,000 after buying an additional 283,265 shares during the last quarter. 96.78% of the stock is owned by hedge funds and other institutional investors.

Vaxcyte Stock Performance

NASDAQ:PCVX opened at $58.07 on Monday. Vaxcyte, Inc. has a 12-month low of $29.87 and a 12-month high of $65.00. The stock’s 50 day simple moving average is $54.95 and its 200-day simple moving average is $55.53. The firm has a market cap of $8.64 billion, a P/E ratio of -7.61 and a beta of 1.23.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($1.97) earnings per share for the quarter, topping the consensus estimate of ($2.06) by $0.09. During the same period last year, the company earned ($1.22) EPS. Research analysts forecast that Vaxcyte, Inc. will post -7.65 EPS for the current fiscal year.

Insider Activity

In other news, CEO Grant Pickering sold 22,461 shares of the business’s stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $52.50, for a total transaction of $1,179,202.50. Following the transaction, the chief executive officer directly owned 474,703 shares in the company, valued at $24,921,907.50. The trade was a 4.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Harpreet S. Dhaliwal sold 17,000 shares of the stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $55.00, for a total transaction of $935,000.00. Following the transaction, the insider directly owned 76,756 shares of the company’s stock, valued at $4,221,580. This represents a 18.13% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 120,646 shares of company stock worth $6,570,810 in the last 90 days. Corporate insiders own 3.30% of the company’s stock.

Wall Street Analysts Forecast Growth

PCVX has been the topic of a number of research reports. Zacks Research upgraded shares of Vaxcyte from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 12th. Wall Street Zen upgraded shares of Vaxcyte from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 8th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a research note on Monday, July 6th. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $86.00.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.